 |
市场调查报告书
商品编码
1528953
甲状腺癌诊断市场规模- 按产品（仪器、套件和消耗品）、类型（乳头状癌、滤泡状癌）、技术（血液检测、影像、活检）、最终用途（医院、癌症诊断中心）和预测，2024 年 - 2032Thyroid Cancer Diagnostics Market Size - By Product (Instruments, Kits and Consumables), Type (Papillary Carcinoma, Follicular Carcinoma), Technique (Blood Test, Imaging, Biopsy), End-use (Hospitals, Cancer Diagnostic Centers) & Forecast, 2024 - 2032 |
||||||
由于伙伴关係和合作的增加以及持续的技术进步，2024 年至 2032 年全球甲状腺癌诊断市场规模将以 5.7% 的复合年增长率扩大。研究人员和医疗专业人员正在改进多种诊断方法，以提高准确性和早期检测能力。他们正在整合先进的成像技术和分子生物标记来提高诊断准确性。
人工智慧驱动演算法的利用等快速进步也透过开发用于治疗计划和预后评估的下一代诊断工具来提高精确度。例如，2023 年 10 月，核医领域的领导者 Curium 和 3D 超音波解决方案的先驱 PIUR IMAGING 合作，在德国推进甲状腺癌诊断。
市场分为产品、类型、技术、最终用途和地区。
按产品类型划分，由于需要提高准确性和简化诊断流程，预计从 2024 年到 2032 年，试剂盒和耗材领域的甲状腺癌诊断市场将大幅成长。製造商正在开发创新的生物标记测定和成像剂，以提高检测甲状腺癌标记的灵敏度和特异性。此外，先进生物感测技术和小型化晶片实验室设备的整合等发展正在扩大可用套件和耗材的范围，以实现快速且经济高效的测试。
癌症诊断中心最终用途领域的甲状腺癌诊断产业预计将从 2024 年扩大到 2032 年。这些中心的医疗专业人员正在完善方案并采用新的方法来改善患者的治疗结果。癌症诊断中心的不断进步将进一步为患者提供更快、更准确的诊断和量身定制的治疗策略，以确保更好地管理甲状腺癌并提高整体存活率。
从地区来看，在监管支持和医疗基础设施进步的推动下，欧洲甲状腺癌诊断行业规模预计将在 2024 年至 2032 年间实现强劲增长。欧洲的监管框架正在不断发展，以确保诊断技术的安全性和有效性，从而促进创新和采用。医疗保健基础设施的改善也将促进该地区更多地获得先进的诊断工具和专业知识。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 甲状腺癌盛行率增加
- 癌症诊断技术的进步
- 透过筛检计划提高认识
- 产业陷阱与挑战
- 严格的监管场景
- 甲状腺癌诊断费用高
- 成长动力
- 成长潜力分析
- 技术景观
- 监管环境
- 未来市场趋势
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略展望矩阵
第 5 章：市场估计与预测：按产品分类，2021 - 2032 年
- 主要趋势
- 仪器仪表
- 套件和消耗品
第 6 章：市场估计与预测：按类型，2021 - 2032
- 主要趋势
- 乳头状癌
- 滤泡性癌
- 其他类型
第 7 章：市场估计与预测：按技术分类，2021 - 2032 年
- 主要趋势
- 验血
- 影像学
- 活检
- 其他技术
第 8 章：市场估计与预测：按最终用途，2021 - 2032 年
- 主要趋势
- 医院
- 癌症诊断中心
- 学术及研究机构
- 其他最终用户
第 9 章：市场估计与预测：按地区，2021 - 2032
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区
第 10 章：公司简介
- Abbott Laboratories
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Canon Inc.
- Danaher Corporation
- Esaote SPA
- F. Hoffmann-La Roche Ltd
- GE HealthCare
- Hologic, Inc.
- Illumina, Inc.
- Koninklijke Philips N.V.
- PerkinElmer, Inc.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Veracyte, Inc.
Global Thyroid Cancer Diagnostics Market size will expand at 5.7% CAGR from 2024 to 2032, due to increasing partnerships and collaborations alongside ongoing technological advancements. Researchers and medical professionals are improving several diagnostic methods to enhance accuracy and early detection capabilities. They are integrating advanced imaging techniques and molecular biomarkers to refine diagnostic accuracies.
Rapid advancements, such as the utilization of AI-driven algorithms are also enhancing precision through the development of next-generation diagnostic tools for treatment planning and prognostic assessment. For instance, in October 2023, Curium, a leader in nuclear medicine, and PIUR IMAGING, a pioneer in 3D ultrasound solutions, partnered to advance thyroid cancer diagnostics in Germany.
The market is segregated into product, type, technique, end-use, and region.
By product type, the thyroid cancer diagnostics market from the kits & consumables segment is estimated to rise at significant rate from 2024 to 2032 due to the need for improved accuracy and streamlined diagnostic processes. Manufacturers are developing innovative biomarker assays and imaging agents to enhance sensitivity and specificity in detecting thyroid cancer markers. In addition, developments like the integration of advanced biosensing technologies and miniaturized lab-on-a-chip devices are expanding the range of available kits and consumables for rapid and cost-effective testing.
Thyroid cancer diagnostics industry from the cancer diagnostic centers end-use segment is expected to expand from 2024 to 2032. This is owing to the increasing integration of state-of-the-art imaging technologies and molecular testing capabilities to enhance diagnostic accuracy and treatment planning. Medical professionals at these centers are refining protocols and adopting new methodologies to improve patient outcomes. The ongoing advancements in cancer diagnostic centers will further provide patients with faster, more accurate diagnoses and tailored therapeutic strategies for ensuring better management of thyroid cancer and improved overall survival rates.
Regionally, the Europe thyroid cancer diagnostics industry size is projected to depict robust growth between 2024 and 2032, propelled by regulatory support and advancements in healthcare infrastructure. Regulatory frameworks in Europe are evolving to ensure the safety and efficacy of diagnostic technologies for fostering innovation and adoption. Healthcare infrastructure improvements will also facilitate greater access to advanced diagnostic tools and expertise across the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of thyroid cancer
- 3.2.1.2 Advancement in cancer diagnostic technologies
- 3.2.1.3 Growing awareness through screening programs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Stringent regulatory scenario
- 3.2.2.2 High cost of thyroid cancer diagnosis
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Instruments
- 5.3 Kits and consumables
Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Papillary carcinoma
- 6.3 Follicular carcinoma
- 6.4 Other types
Chapter 7 Market Estimates and Forecast, By Technique, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Blood test
- 7.3 Imaging
- 7.4 Biopsy
- 7.5 Other techniques
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Cancer diagnostic centers
- 8.4 Academic and research institutes
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Agilent Technologies, Inc.
- 10.3 Bio-Rad Laboratories, Inc.
- 10.4 Canon Inc.
- 10.5 Danaher Corporation
- 10.6 Esaote SPA
- 10.7 F. Hoffmann-La Roche Ltd
- 10.8 GE HealthCare
- 10.9 Hologic, Inc.
- 10.10 Illumina, Inc.
- 10.11 Koninklijke Philips N.V.
- 10.12 PerkinElmer, Inc.
- 10.13 Siemens Healthineers AG
- 10.14 Thermo Fisher Scientific Inc.
- 10.15 Veracyte, Inc.
